

TABLE OF CONTENTS

	Page
ACKNOWLEDGEMENT	iii
ENGLISH ABSTRACT	iv
THAI ABSTRACT	vi
LIST OF TABLES	ix
LIST OF ILLUSTRATIONS	x
LIST OF ABBREVIATIONS	xi
INTRODUCTION	1
LITERATURE REVIEW	6
OBJECTIVES	21
MATERIALS AND METHODS	22
RESULTS	29
DISCUSSION	38
CONCLUSION	41
REFERENCES	42
APPENDIX	56
VITA	58

LIST OF TABLES

Table		Page
1	Demographic characteristics of lung cancer patients in the study.	31
2	Randomization sequences of treatment cycle.	32
3	Urinary NAG activities (unit/gram creatinine) of lung cancer patients treated with cisplatin alone and cisplatin plus fosfomycin.	33
4	Creatinine clearance (mL/min) of lung cancer patients treated with cisplatin alone and cisplatin plus fosfomycin.	34
5	Serum creatinine (mg/dL) in lung cancer patients treated with cisplatin alone and cisplatin plus fosfomycin.	35
6	Urine NAG activities before and after 100 mg/m ² cisplatin administration.	36
7	Creatinine clearance (mL/min) before and after 100 mg/m ² cisplatin administration.	36
8	Serum creatinine (mg/dL) before and after 100 mg/m ² cisplatin administration.	37

LIST OF ILLUSTRATIONS

Figure		Page
Figure 1	Structure of cisplatin	8
Figure 2	Structure of Fosfomycin sodium	16

มหาวิทยาลัยเชียงใหม่
Chiang Mai University

LIST OF ABBREVIATIONS

ALT	alanine aminotransferase
AST	aspartate aminotransferase
BUN	blood urea nitrogen
BW	body weight
CL	clearance
CL _{cr}	creatinine clearance
conc.	concentration
dL	deciliter
gm	gram
GFR	glomerular filtration rate
hr	hour
Hb	haemoglobin
Hct	haematocrit
kg	kilogram
L	litter
LDH	lactate dehydrogenase
m	meter
M	molar
Mfd.	manufactured date
mg	milligram
min	minute
mL	milliliter
μL	microliter

mm	millimeter
mM	millimolar
NAG	N-acetyl- β -D-glucosaminidase
No.	number
NSAIDs	nonsteroidal antiinflammatory drugs
NSCLC	non-small cell lung cancer
$^{\circ}\text{C}$	degree Celsius
PS	performance status
Scr	serum creatinine concentration
S.D.	standard deviation
$T_{1/2}$	elimination half-life
USP	The United States Pharmacopoeia
WBC	white blood cell
yr	year